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The presence of multiple alloantibodies or an antibody to a high-
prevalance antigen in a patient sample can pose challenges in 
antibody identification. The pattern of reactivity seen on an 
antibody panel may show various strengths of reactivity by 
different methods of testing or same strength of reactivity at 
one or more phases of testing. To ensure proper identification, 
multiple investigative tools may be used. We review one of 
these methods—inhibition by soluble substances—which has 
become an expansion of our toolbox within the past 10 years. 
Alloantibodies can be inhibited using specific soluble substances. 
These soluble substances occur naturally in various fluids or 
can be manufactured. When a patient sample contains multiple 
antibodies, clinically significant or not, inhibition of one may 
help determine specificities of others. Specific inhibition of 
a particular antibody will also help to confirm its presence. 
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Background
When performing pretransfusion testing, serologic results 
may indicate the presence of one or more alloantibodies. 
There are many methods that can be used to identify and 
separate specificities.1 One such method is based on the 
principle of inhibition. The ability to specifically inhibit one 
antibody may help identify that antibody and allow other 
antibody specificities to also be identified. Inhibition can aid 
in the identification of an antibody to an antigen that shows 
variable expression among individuals, such as anti-P1. Some 
antibodies can be inhibited by soluble substances such as 
sugars, proteins, and peptides; examples include ABH, Lewis, 
P1, Sda, Chido/Rodgers, and ID. Human saliva, hydatid cyst 
fluid, pigeon egg white, human or guinea pig urine, human 
serum, and human milk have been used as soluble substances 
to inhibit red blood cell (RBC) antibodies before the 1990s.1–4
Since then, recombinant blood group proteins (rBGPs) 
have also been shown to be effective in the identification of 
antibodies to high-prevelance antigens that are single pass 
and glycosylphosphatidylinositol-linked proteins, thus leading 
to the detection of underlying alloantibodies.5–8 Unlike tradi-
tional soluble substances that are found naturally in human 
and other animal sources, rBGPs are manufactured.5–7 The 
result of the manufacturing is a very specific rBGP that could 
aid in antibody identification.7 Gone are the days when the only 
tools available to the investigational immunohematologist were 
RBCs, polyclonal antibodies, lectins, and natural inhibitory 
substances.9 Recombinant peptides and proteins represent the 
latest addition to our growing toolbox.
Principle
Inhibition takes place when plasma or serum containing 
an antibody is incubated with a soluble substance (natural or 
synthentic) of corresponding specificity. Subsequent testing 
(hemagglutination) reveals the lack of reactivity with RBCs 
that tested positive before inhibition. Other antibodies, if 
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Reagents/Supplies
Reagents Supplies
• Reactive blood sample (plasma or 
serum)
• Soluble substance (antigen, natural, or 
synthetic)
• Inert substance, such as albumin or 
saline
• Other reagents as appropriate, such as 
anti-IgG, IgG-coated RBCs
• Test tubes (gel cards 





RBCs = red blood cells.
Procedural Steps
• Prepare soluble substance for use.
• Mix soluble substance with test sample.
• Prepare a dilution control containing equal volumes of test sample 
and an inert substance, such as albumin or saline.
• Incubate at optimal temperature and time.
• Test the sample plus the substance and the sample plus the inert 
substance (dilution control) against RBCs that previously gave a 
positive reaction.
RBCs = red blood cells.
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present, in treated plasma or serum should remain unaffected 
and can be identified. The principle of this reaction is based 
on the inhibition of the antibody by the corresponding soluble 
protein.
Indications
Inhibition of blood group antibodies by soluble substances 
can aid in the identification of specific antibodies. Antibody 
activity of known specificity can be selectively “removed” 
by using the inhibition method, thus leaving behind other 
antibodies to be identified. Other indications for inhibition are 
to determine ABH secretor status and immunoglobulin class 
of anti-A and/or anti-B. Inhibition using rBGP has also helped 
classify a new blood group antigen, CD59.6 One may consider 
using rBGPs based on serological clues of the specimen and 
the availability and specificity of the rBGP.
Soluble Substances
One must determine the appropriate soluble substance 
to use. Today, the choices are many (Table 1). Blood group 
substances in water-soluble form in tissue fluids and secretions 
of the body have been known since the 1930s.10 Agglutination 
inhibition tests using A and B substances and boiled saliva were 
being used as early as 1940.11,12 In 1996, soluble CR1 produced 
by recombinant DNA techniques was used to identify Knops 
system antibodies.13
The latest development is the use of soluble proteins to 
inhibit drugs in the plasma and serum of patients who are 
treated with monoclonal antibodies. Besides the surface 
proteins on the target cells, some of this novel drug binds 
to RBCs. Examples are anti-CD3814,15 and anti-CD4716 
monoclonal antibody therapy. Both drugs can be inhibited by 
recombinant soluble proteins, CD3817 and CD47 (unpublished 
results), although their high titers in patients may preclude 
the effective inhibition in neat plasma samples. A recent 
article by Velliquette et al.18 evaluated anti-CD47 (Hu5F9-G4) 
interference in pretransfusion testing and offered mitigation 
strategies. Covering the target blood group antigens on the 
RBC surface is another approach. This novel and attractive 
alternative will add to our toolbox and should eventually 
become the topic of another review.
Procedure
Obtain plasma or serum sample for testing. If necessary, 
process the substance (Table 2). Once ready for testing, the 
most common procedure starts with labeling two test tubes: 
one for the sample and one for the dilution control. Combine 
test sample and soluble substance into the tube labeled 
“sample.” To the tube labeled “dilution control,” combine test 
sample and inert substance. Incubate both tubes for a specific 
time and temperature determined by the known “ideal” for 
the target specificity. After incubation, test samples against 
previously reactive RBCs selected by phenotype. Inhibition 
has occurred when the “sample” is nonreactive and the 
“dilution control” is still reactive. These results confirm 
that inhibition of antibody has taken place and the lack of 
reactivity was not caused by dilution. If the “dilution control” 
Table 1. Known soluble substances and their use
Blood group system ISBT number Antibody inhibited Immmunoglobulin class Soluble substance
ABO 001 Anti-A; anti-B IgM; IgG Human saliva (secretor)
H 018 Anti-H IgM Human saliva (secretor)
Lewis 007 Anti-Lea; anti-Leb IgM Human saliva (secretor)
P1PK 003 Anti-P1 IgM Hydatid cyst fluid, pigeon 
egg albumin
901 series 901 Anti-Sda IgM>IgG Human urine or saliva, 
guinea pig urine
Chido/Rodgers 017 Anti-Ch; anti-Rg IgG Pooled plasma
Cromer 021 Most Cromer antibodies IgG Human serum, plasma, or 
concentrated urine
Scianna 013 Anti-Sc1 (Seltsam et al.5) IgG Recombinant protein
CD59, Lutheran, Yt, Dombrock, Chido/
Rodgers, Cromer, Knops, JMH
035, 005, 011, 014, 
017, 021, 022, 026
See Anliker et al.6 and 
Seltsam et al.7
Usually IgG Soluble recombinant 
proteins from eukaryotic 
expression systems
ISBT = International Society of Blood Transfusion.
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is nonreactive, the test is invalid. The hemagglutination test 
can be done in tubes as described here or by other methods 
such as column agglutination or solid phase if recommended 
by the manufacturer or validated in-house.
Limitations
A positive reaction when testing the sample plus soluble 
substance may indicate that additional alloantibodies are 
present in the sample. Testing additional RBCs using the 
sample plus soluble substance may be indicated to determine 
possible additional antibody specificities. It may not be 
possible to test low-titer antibodies because of the required 
dilution that cannot be achieved. If one wants to use specific 
rBGPs, they are commercially available if the molecular and 
genetic basis are known.20 It may not always be possible to 
inhibit high-titer antibodies, particularly monoclonal antibody 
drug formulations, because the required high concentration of 
the soluble substance cannot be achieved.
Quality Control
The dilution control containing the sample plus inert 
substance should result in a positive reaction when tested 
against an RBC positive for the corresponding antigen to the 
antibody under investigation. The lack of reactivity in the 
dilution control indicates dilution of weakly reactive low-titer 
antibody and invalidates the test.
Precautions
Use caution when using any of these soluble substances. 
Follow the procedure as written and test using the 
recommended test system, such as tube or gel method. For 
example, if one chooses to change from testing in tube to gel 
method, the nonstandard test method should be validated 
before use. Immunoglobulin class (IgG versus IgM) should be 
considered when evaluating an unexpected result, such as a 
false positive.
Summary
Inhibition has proven to be useful in separating, 
identifying, and detecting alloantibodies that may be present 
in a patient’s sample. Traditional sources (saliva, plasma, and 
urine) of soluble substances and anti-drug proteins can be 
used to inhibit antibodies, allowing for their detection and 
identification. The use of rBGPs has expanded our ability to 
inhibit a greater number of antibody specificities and can 
be used in different assays to detect and identify distinct 
antibodies.
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Table 2. Preparation of soluble substances
Source material Preparation
Guinea pig urine After collection of urine, boil for 10 minutes. 
Dialyze for 48 h at 4°C against multiple changes 
of pH 7.4 PBS. Centrifuge, aliquot, and freeze.19
Human milk Collect milk from lactating women, centrifuge at 
1000g (serofuge at 3400 rpm) for 10 minutes, 
remove and discard the cream layer, incubate 
milk in boiling water for 10 minutes, mix 1 volume 
of milk with 1 volume of PBS. Aliquot and 
freeze.2 
Human saliva Collect 2 mL saliva, boil for 10 minutes, 
centrifuge at 1000g (serofuge at 3400 rpm) 
for 10 minutes, harvest supernate, aliquot, and 
freeze.2
Human urine Collect urine from three individuals, pool, 
centrifuge, dilute with equal volume of distilled 
water, check pH (dialysis with PBS may be 
needed to obtain pH between 6 and 8.5), 
aliquot, and store frozen until needed.2
Hydatid cyst fluid Incubate HCF (with scolices) from animal or 
human sources at 56°C for 1 hour. Dilute 1 
volume of hydatid cyst fluid with 9 volumes of 
PBS. Aliquot and freeze.2 
Pigeon egg albumin Separate egg white from the yolk. Prepare 
dilutions of 1:100 to 1:1000 in PBS. Test the 
dilutions using a potent anti-P1 to determine the 
best dilution for inhibition studies. Make aliquots 
of appropriate dilution and freeze.2
Pooled plasma Purchase commercial pooled plasma or prepare 
pooled plasma from six or more donors. Aliquot 
and freeze.3
Recombinant protein May be commercially available.5–7,15
PBS = phosphate-buffered saline.
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